Literature DB >> 19689240

Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects.

Chera L Maarouf1, Tracy M Andacht, Tyler A Kokjohn, Eduardo M Castaño, Lucia I Sue, Thomas G Beach, Alex E Roher.   

Abstract

A crucial need exists for reliable Alzheimer's disease (AD) diagnostic and prognostic tests. Given its intimate communication with the brain, the cerebrospinal fluid (CSF) has been surveyed intensively for reliable AD biomarkers. The heterogeneity of AD pathology and the unavoidable difficulties associated with the clinical diagnosis and differentiation of this dementia from other pathologies have confounded biomarker studies in antemortem CSF samples. Using postmortem ventricular CSF (V-CSF) pools, two-dimensional difference gel electrophoresis (2D DIGE) analyses revealed a set of proteins that showed significant differences between neuropathologically-diagnosed AD and elderly non-demented controls (NDC), as well as subjects with non-AD dementias. The 2D DIGE system identified a set of 21 different protein biomarkers. This panel of proteins probably reflects fundamental pathological changes that are divergent from both normal aging and non-AD dementias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689240      PMCID: PMC2832860          DOI: 10.2174/156720509788929318

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  44 in total

1.  Dynamics of brain-derived proteins in cerebrospinal fluid.

Authors:  H Reiber
Journal:  Clin Chim Acta       Date:  2001-08-20       Impact factor: 3.786

Review 2.  Multi-functional capability of proteins: alpha1-antichymotrypsin and the correlation with Alzheimer's disease.

Authors:  Shuguang Zhang; Sabina Janciauskiene
Journal:  J Alzheimers Dis       Date:  2002-04       Impact factor: 4.472

3.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

4.  Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils.

Authors:  I Ray; A Chauhan; J Wegiel; V P Chauhan
Journal:  Brain Res       Date:  2000-01-24       Impact factor: 3.252

5.  Fibulin-1 binds the amino-terminal head of beta-amyloid precursor protein and modulates its physiological function.

Authors:  I Ohsawa; C Takamura; S Kohsaka
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

6.  Binding of gelsolin, a secretory protein, to amyloid beta-protein.

Authors:  V P Chauhan; I Ray; A Chauhan; H M Wisniewski
Journal:  Biochem Biophys Res Commun       Date:  1999-05-10       Impact factor: 3.575

Review 7.  Polymorphisms in inflammatory genes and the risk of Alzheimer disease.

Authors:  P L McGeer; E G McGeer
Journal:  Arch Neurol       Date:  2001-11

8.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Authors:  Maja Puchades; Sara Folkesson Hansson; Carol L Nilsson; Niels Andreasen; Kaj Blennow; Pia Davidsson
Journal:  Brain Res Mol Brain Res       Date:  2003-10-21

9.  Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?

Authors:  S Yamagishi; Y Inagaki; M Takeuchi; N Sasaki
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

10.  Cerebrospinal fluid levels of beta-amyloid(42) in patients with Alzheimer's disease are related to the exon 2 polymorphism of the cathepsin D gene.

Authors:  Andreas Papassotiropoulos; Huw D Lewis; Metin Bagli; Frank Jessen; Ursula Ptok; Andrea Schulte; Mark S Shearman; Reinhard Heun
Journal:  Neuroreport       Date:  2002-07-19       Impact factor: 1.837

View more
  10 in total

1.  The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species.

Authors:  Jessica M Mc Donald; Tiernan T O'Malley; Wen Liu; Alexandra J Mably; Gunnar Brinkmalm; Erik Portelius; William M Wittbold; Matthew P Frosch; Dominic M Walsh
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

Review 2.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

3.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

4.  Cerebrospinal fluid proteome of patients with acute Lyme disease.

Authors:  Thomas E Angel; Jon M Jacobs; Robert P Smith; Mark S Pasternack; Susan Elias; Marina A Gritsenko; Anil Shukla; Edward C Gilmore; Carol McCarthy; David G Camp; Richard D Smith; H Shaw Warren
Journal:  J Proteome Res       Date:  2012-08-31       Impact factor: 4.466

5.  Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Terence Wu; Douglas G Walker; Tyler A Kokjohn; Alex E Roher
Journal:  Neurol Res       Date:  2012-09       Impact factor: 2.448

6.  The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.

Authors:  Thomas E Angel; Jon M Jacobs; Serena S Spudich; Marina A Gritsenko; Dietmar Fuchs; Teri Liegler; Henrik Zetterberg; David G Camp; Richard W Price; Richard D Smith
Journal:  Clin Proteomics       Date:  2012-03-20       Impact factor: 3.988

7.  Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Douglas G Walker; Jesse M Hunter; Jane C Kruchowsky; Randy Woltjer; Jeffrey Kaye; Eduardo M Castaño; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

Review 8.  Proteomics and metabolomics in ageing research: from biomarkers to systems biology.

Authors:  Jessica M Hoffman; Yang Lyu; Scott D Pletcher; Daniel E L Promislow
Journal:  Essays Biochem       Date:  2017-07-11       Impact factor: 7.258

9.  A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.

Authors:  Daniel A Llano; Saurabh Bundela; Raksha A Mudar; Viswanath Devanarayan
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

Review 10.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.

Authors:  Juan R Peinado; Yoana Rabanal-Ruiz; Cristina M Pedrero-Prieto; Sonia García-Carpintero; Javier Frontiñán-Rubio; Emilio Llanos-González; Cristina Aguilera García; Francisco J Alcaín; Iris Lindberg; Mario Durán-Prado
Journal:  Clin Proteomics       Date:  2020-06-05       Impact factor: 3.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.